New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:09 EDTWXWuXi PharmaTech, Pacific Biomarkers announce collaboration
WuXi PharmaTech and Pacific Biomarkers announced a biomarker collaboration. In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
16:48 EDTWXWuXi PharmaTech acknowledges partner TaiMed Biologics for orphan designation
WuXi PharmaTech congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients. "We commend TaiMed's great progress in advancing this important life-saving therapy," said Dr. Ge Li, Chairman and CEO of WuXi. "This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China."
October 22, 2014
08:22 EDTWXFoundation Medicine, WuXi PharmaTech announce strategic collaboration
Foundation Medicine (FMI) and WuXi PharmaTech (WX) announced a collaboration to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
08:13 EDTWXFoundation Medicine, WuXi PharmaTech announce collaboration
Subscribe for More Information
October 20, 2014
07:10 EDTWXAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use